Saturday, September 14, 2024 3:16:15 PM
I am writing a book, American Cars of 1958. Check often for the latest addition. https://investorshub.advfn.com/American-Cars-of-1958-37252/
Recent MIRM News
- Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 12/10/2024 11:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/15/2024 10:34:54 PM
- Mirum Pharmaceuticals to Showcase Data from its LIVMARLI and Volixibat Clinical Programs at AASLD’s The Liver Meeting • Business Wire • 11/14/2024 01:00:00 PM
- Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 11/12/2024 04:44:27 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/12/2024 01:14:55 PM
- Mirum Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update • Business Wire • 11/12/2024 01:00:00 PM
- Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 11/08/2024 11:30:00 PM
- Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences • Business Wire • 11/07/2024 09:30:00 PM
- Mirum Pharmaceuticals to Announce Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024 • Business Wire • 11/04/2024 09:30:00 PM
- Mirum Pharmaceuticals to Showcase LIVMARLI Data from its ALGS and PFIC Programs at the NASPGHAN Annual Meeting • Business Wire • 10/31/2024 12:30:00 PM
- Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 10/10/2024 11:30:00 PM
- Volixibat Granted Breakthrough Therapy Designation for Cholestatic Pruritus in Primary Biliary Cholangitis • Business Wire • 10/10/2024 12:30:00 PM
- Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 09/11/2024 12:45:00 AM
- Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences • Business Wire • 08/28/2024 08:01:00 PM
- Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 08/09/2024 11:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/07/2024 08:11:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/07/2024 08:06:00 PM
- Mirum Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update • Business Wire • 08/07/2024 08:01:00 PM
- Mirum Pharmaceuticals to Announce Second Quarter 2024 Financial Results and Host Conference Call on August 7, 2024 • Business Wire • 07/31/2024 08:30:00 PM
- Mirum’s LIVMARLI Now Approved for PFIC in Patients 12 Months and Older • Business Wire • 07/25/2024 12:30:00 PM
- Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 07/10/2024 11:00:00 PM
- Approbation du LIVMARLI de Mirum Pharmaceuticals dans l'Union européenne pour les patients atteints de PFIC • Business Wire • 07/08/2024 08:46:00 PM
- LIVMARLI von Mirum Pharmaceuticals wird in der Europäischen Union für Patienten mit PFIC zugelassen • Business Wire • 07/08/2024 08:20:00 PM
- Mirum Pharmaceuticals’ LIVMARLI Approved in the European Union for Patients with PFIC • Business Wire • 07/08/2024 12:30:00 PM
UAV Corp. (UMAV) Reduces Authorized Shares by 1.2 Billion, Demonstrating Commitment to Shareholders; New Authorized Share Count Approved at 800 Million • UMAV • Dec 17, 2024 12:00 PM
Avant Technologies and Ainnova Secure Advanced AI Algorithms for Early Detection of Four Additional Diseases in the U.S. • AVAI • Dec 17, 2024 8:00 AM
North Bay Resources Announces MET Results of 97% Gold Recovery with Upgrade to 11.2 Ounces per Ton Concentrate, Fran Gold Project; Completes 120 Ton Winter Ore Shipment • NBRI • Dec 16, 2024 9:00 AM
Mass Megawatts Announces the Financial Reporting Status Being Current as of Today • MMMW • Dec 16, 2024 8:18 AM
VAYK Renewed JV to Renovate Historic Landmark into "Most Sought-after Airbnb Place" in Downtown Atlanta • VAYK • Dec 12, 2024 9:36 AM
Silexion Is Addressing the MOST COMMON Human Cancer Gene Mutation With RNAi; Recent M&As in the Field Were for Tens of Billions - $SLXN • SLXN • Dec 11, 2024 9:22 AM